|
PPP6C expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.41880000004146E-06 |
| Normal-vs-Stage3 |
2.66453525910038E-15 |
| Normal-vs-Stage4 |
1.62503344114384E-12 |
| Stage1-vs-Stage2 |
2.626200E-01 |
| Stage1-vs-Stage3 |
1.935150E-01 |
| Stage1-vs-Stage4 |
9.435200E-03 |
| Stage2-vs-Stage3 |
5.865900E-02 |
| Stage2-vs-Stage4 |
6.581400E-03 |
| Stage3-vs-Stage4 |
1.585600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.25109999999673E-05 |
| Normal-vs-Asian |
2.13484785405171E-12 |
| Caucasian-vs-AfricanAmerican |
1.730370E-01 |
| Caucasian-vs-Asian |
5.101800E-01 |
| AfricanAmerican-vs-Asian |
1.653630E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33066907387547E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.469800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.6251444634463E-12 |
| Normal-vs-Age(41-60Yrs) |
1.88737914186277E-15 |
| Normal-vs-Age(61-80Yrs) |
1.9453327837482E-12 |
| Normal-vs-Age(81-100Yrs) |
8.1588999999993E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.686200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.940800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.787000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.039200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.388400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.126800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.522200E-01 |
| Classical-VS-Follicular |
4.129400E-01 |
| Classical-VS-Other |
2.163200E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
5.018000E-02 |
| Tall-VS-Other |
5.752800E-01 |
| Tall-VS-Normal |
6.60820287379238E-11 |
| Follicular-VS-Other |
2.021600E-01 |
| Follicular-VS-Normal |
3.85739995500956E-09 |
| Other-VS-Normal |
3.77169999999927E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.80886425230165E-14 |
| Normal-vs-N1 |
7.43849426498855E-15 |
| N0-vs-N1 |
9.957300E-03 |
|
|
